nature portfolio

Corresponding author(s):	DBPR COMMSBIO-22-2482B

Last updated by author(s): Oct 12, 2022

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

< ∙	tっ	1		۲ı	~
.)	ıd	ш	1.5	ıI	CS

For	all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed
	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
	A description of all covariates tested
	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
	Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

Software and code

Policy information about <u>availability of computer code</u>

Data collection No unreported custom computer code or algorithm was used.

Data analysis No unreported custom computer code or algorithm was used.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The genome assembly reported in this paper is associated with NCBI BioProject: PRJNA738334 and BioSample: SAMN19718602. The detailed sequencing information have been deposited in NCBI's Sequence Read Archive under accession numbers SRR14933280 and SRR14933281. An annotated gff3 file was shown in Supplementary Data 12. DAP-seq and RNA seq data underlying the findings described in the manuscript are fully available without restriction from the Bioproject

· ·		4162-64 and SRR20305604-09, respectively. The raw data for Fig. 4e, 5d, S4d, S4e were shown in Supplementary Data 13. upplementary Figure 6.				
Human rese	arch pa	rticipants				
	· · ·	es involving human research participants and Sex and Gender in Research.				
Reporting on sex and gender		This study don't involve human research participants and Sex and Gender in Research.				
Population characteristics		This study don't involve human research participants and Sex and Gender in Research.				
Recruitment		This study don't involve human research participants and Sex and Gender in Research.				
Ethics oversight		This study don't involve human research participants and Sex and Gender in Research.				
Note that full informa	ation on the a	approval of the study protocol must also be provided in the manuscript.				
•		reporting at is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.				
∑ Life sciences		Behavioural & social sciences				
For a reference copy of	the document v	with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>				
Lite scier	nces s	tudy design				
		ese points even when the disclosure is negative.				
Sample size	No sample-	size calculation was performed.				
Data exclusions	No date we	re excluded from the analyses.				
Replication	The data fro	The data from three independent replicates.				
Randomization	Our researce	Our research sample is fungus Ganoderma lingzhi, don't involve randomization.				
Blinding	This study o	don't involve blinding.				
We require informati	ion from auth	specific materials, systems and methods ors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.				
Materials & ex	perimenta	al systems Methods				
n/a Involved in th	,	n/a Involved in the study				
	✓ Antibodies ✓ ChIP-seq ☐ Eukaryotic cell lines ✓ Flow cytometry					
	logy and arch					
Animals ar	nd other orga	nisms .				
Clinical dat	ta esearch of coi	ncern				
	escuren or col					
Antibodies						
Antibodies used	β-4	Actin antibody; β-Tubulin antibody; Histone-H3 antibody; polyclonal antibody against SREBP.				
Validation	CN	Actin antibody (1:2000, AT0097, CMCTAG); β-Tubulin antibody (1:2000, AT0003, CMCTAG); Histone-H3 antibody (1:2000, AT0005, MCTAG) ;polyclonal antibody against SREBP (immunization of rabbits with the SREBP-bHLH protein by a professionally qualified tibody preparation company). The results of Western blot analysis using these antibodies are shown in Figure S4.				